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Genome wide meta-analysis identifies genomic relationships, novel loci, and 
pleiotropic mechanisms across eight psychiatric disorders.   
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Genetic influences on psychiatric disorders transcend diagnostic boundaries, 
suggesting substantial pleiotropy of contributing loci. However, the nature and 
mechanisms of these pleiotropic effects remain unclear. We performed a meta-analysis 
of 232,964 cases and 494,162 controls from genome-wide studies of anorexia nervosa, 
attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major 
depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome. 
Genetic correlation analyses revealed a meaningful structure within the eight disorders 
identifying three groups of inter-related disorders. We detected 109 loci associated with 
at least two psychiatric disorders, including 23 loci with pleiotropic effects on four or 
more disorders and 11 loci with antagonistic effects on multiple disorders. The 
pleiotropic loci are located within genes that are disproportionately expressed in the 
brain throughout the lifespan, beginning in the second trimester prenatally, and play 
prominent roles in a suite of neurodevelopmental processes. These findings have 
important implications for psychiatric nosology, drug development, and risk prediction. 
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Psychiatric disorders affect more than 25% of the population in any given year and are 
a leading cause of worldwide disability (Disease et al., 2017; Kessler and Wang, 2008).  
The substantial influence of genetic variation on risk for a broad range of psychiatric 
disorders has been established by both twin and, more recently, large-scale genomic 
studies (Smoller et al., 2018). Psychiatric disorders are highly polygenic, with a large 
proportion of heritability contributed by common variation. Many risk loci have emerged 
from genome-wide association studies (GWAS) of, among others, schizophrenia (SCZ), 
bipolar disorder (BIP), major depression (MD), and attention-deficit/hyperactivity 
disorder (ADHD) from the Psychiatric Genomics Consortium (PGC) and other efforts 
(Sullivan et al., 2018). These studies have revealed a surprising degree of genetic 
overlap among psychiatric disorders(Brainstorm et al., 2018). Elucidating the extent and 
biological significance of cross-disorder genetic influences has implications for 
psychiatric nosology, drug development, and risk prediction. In addition, characterizing 
the functional genomics of cross-phenotype genetic effects may reveal fundamental 
properties of pleiotropic loci that differentiate them from disorder-specific loci, and help 
identify targets for diagnostics and therapeutics.  
In 2013, analyses by the PGC’s Cross-Disorder Workgroup identified loci with 
pleiotropic effects across five disorders: autism spectrum disorder (ASD), ADHD, SCZ, 
BIP, and MD in a sample comprising 33,332 cases and 27,888 controls 'Smoller, 2013 
#11061. In the current study, we examined pleiotropic effects in a greatly expanded 
dataset, encompassing 232,964 cases and 494,162 controls, that included three 
additional psychiatric disorders: Tourette syndrome (TS), obsessive-compulsive 
disorder (OCD), and anorexia nervosa (AN). We address four major questions 
regarding the shared genetic basis of these eight disorders: 1) Can we identify a shared 
etiologic structure within the broad range of these clinically distinct psychiatric 
disorders? 2) Can we detect additional loci associated with risk for multiple disorders 
(pleiotropic loci)? 3) Do some of these risk loci have opposite allelic effects across 
disorders? and 4) Can we identify functional features of the pleiotropic loci that could 
account for their broad effects on psychopathology?  
  
 
Results   
  
We analyzed genome-wide single nucleotide polymorphism (SNP) data for eight 
neuropsychiatric disorders using a combined sample of 232,964 cases and 494,162 
controls (Table 1; Supplementary Table 1). The eight disorders included AN 'Duncan, 
2017 #12578}, ASD (Grove et al., 2017), ADHD (Demontis et al., 2018), BIP (Stahl et 
al., 2018), MD (Wray et al., 2018), OCD (International Obsessive Compulsive Disorder 
Foundation Genetics and Studies, 2018), TS (Yu et al., In press.), and SCZ 
(Schizophrenia Working Group of the Psychiatric Genomics, 2014). All study 
participants were of self-identified European ancestry, which was supported by principal 
component analysis of genome-wide data.   
 
Table 1. Summary of eight neuropsychiatric disorder 
datasets   
       
Disorder Cases Controls 
Total 









ADHD 19,099 34,194 53,293 0.05 
0.222 (0.014) 
Demontis et al. 2018  
AN 3,495 10,983 14,478 0.01 
0.195 (0.029) 
Duncan et al. 2017 
ASD 18,381 27,969 46,350 0.01 
0.113 (0.010) 
Grove et al. 2017 
BIP 20,352 31,358 51,710 0.01 
0.182 (0.011) 
Stahl et al. 2018 
MD 130,664 330,470 461,134 0.15 
0.085 (0.004) 
Wray et al. 2018 
OCD 2,688 7,037 9,725 0.025 
0.280 (0.041) 
IOCDF-GC and OCGAS 
SCZ 33,640 43,456 77,096 0.01 
0.222 (0.012) 
Schizophrenia Working 
Group of PGC. 2014 
TS 4,645 8,695 13,340 0.008 
0.200 (0.026) 
Yu et al. 2018 
Total 232,964 494,162 727,126   
    
The number of cases and controls used in the meta-analysis of the present study. The numbers may 
differ from those reported in the original publications because our study included only European ancestry 
subjects to avoid potential confounding due to ancestral heterogeneity across distinct disorder studies. 
SNP heritability was estimated from the GWAS summary statistics using LD score regression. 
 
Genetic correlations among eight neuropsychiatric disorders indicate three 
genetic factors.  
After standardized and uniform quality control, additive logistic regression analyses 
were performed on individual disorders (Online Methods). A total of 6,786,994 SNPs 
were common across all datasets and were retained for further study. Using the 
summary statistics of these SNPs, we first estimated pairwise genetic correlations 
among the eight disorders using linkage disequilibrium (LD) score regression analyses 
'Bulik-Sullivan, 2015 #12456} (Online Methods; Fig. 1a; Supplementary Table 2). The 
results were broadly concordant with previous estimates (Brainstorm et al., 2018) 
(Cross-Disorder Group of the Psychiatric Genomics et al., 2013). The genetic 
correlation was highest between SCZ and BIP (rg = 0.70 ±0.02), followed by OCD and 
AN (rg = 0.50 ±0.12). Interestingly, based on genome-wide genetic correlations, MD 
was closely correlated with ASD (rg=0.45 ±0.04) and ADHD (rg=0.44 ±0.03), two 
childhood-onset disorders. Despite variation in magnitude, significant genetic 
correlations were apparent for most pairs of disorders, suggesting a complex, higher-
order genetic structure underlying psychopathology (Fig. 1b).   
  
We modeled the genome-wide joint architecture of the eight neuropsychiatric disorders 
using an exploratory factor analysis (EFA) (Gorsuch, 1988), followed by genomic 
structural equation modeling (SEM) (Grotzinger et al., 2018) (Online Methods). EFA 
identified three correlated factors, which together explained 51% of the genetic variation 
in the eight neuropsychiatric disorders (Supplementary Table 3). The first factor 
consisted primarily of disorders characterized by compulsive behaviors, specifically AN, 
OCD, and, more weakly, TS. The second factor was characterized by mood and 
psychotic disorders (MD, BIP, and SCZ), and the third factor by three early-onset 
neurodevelopmental disorders (ASD, ADHD, TS) as well as MD. Similar to our EFA 
results, hierarchical clustering analyses also identified three sub-groups among the 
eight disorders (Supplementary Fig. 1).   
   
 
1.  
Figure 1. Genetic relationships between eight psychiatric disorders. 
 
 
Cross-disorder meta-analysis identifies 109 pleiotropic loci  
The factor structure described above is based on average effects across the genome, 
but does not address more fine-grained cross-disorder effects at the level of genomic 
regions or individual loci. To identify genetic loci with shared risk, we performed a meta-
analysis of the eight neuropsychiatric disorders using a fixed-effects-based method 
(Bhattacharjee et al., 2012) that accounts for the differences in sample sizes, existence 
of subset-specific effects, and overlapping subjects across datasets (Online Methods). 
There was no evidence of genomic inflation (λ1000 = 1.005; Fig. 2a). Using the primary 
fixed-effects-based meta-analysis, we identified 136 LD-independent regions with 
genome-wide significant association (Pmeta ≤ 5x10
-8). Due to the known extensive LD 
at the major histocompatibility complex (MHC) region (chromosome 6 region at 25-35 
Mb), we considered the multiple signals present there as one locus. 101 of the 136 
(74.3%) significantly associated regions overlapped with previously reported genome-
wide significant regions from at least one individual disorder, while 35 loci (25.7%) 
represented novel genome-wide significant associations.   
  
 










Figure 3. Profile of disorder associations for illustrative pleiotropic loci: (A) 
rs8084351 on 18q21.2; (B) rs7193263 on 16p13.3; (C) rs117956829 on 11q14.3; and 
(D) rs10265001 on 7q34.  
 
Within these 136 loci, multi-SNP-based conditional analysis (Yang et al., 2012) 
identified 10 additional SNPs with independent associations, resulting in a total of 146 
independent lead SNPs (Supplementary Table 4). To provide a quantitative estimate 
of the best fit configuration of cross-disorder genotype-phenotype relationships, we 
estimated the posterior probability of association (referred to as the m-value) with each 
disorder using a Bayesian statistical framework17 (Online Methods; Supplementary 
Table 5). As recommended17, an m-value threshold of 0.9 was used to predict with high 
confidence that a particular SNP was associated with a given disorder. Also, m-values 
of < 0.1 were taken as strong evidence against association. Plots of the SNP p-value vs. 
m-value for all 146 lead SNPs are shown in Supplementary Fig. 2. Nearly 75% (N = 
109/146) of the genome-wide significant SNPs were pleiotropic (i.e., associated  with 
more than one disorder). As expected (Supplementary Fig. 3), configurations of 
disease association reflected the differences in the statistical power and genetic 
correlations between the samples. Of the 109 pleiotropic loci, 83% and 72% involved 
SCZ and BIP, respectively. MD, which had the largest case-control sample, was 
associated with 48% of the pleiotropic loci (N=52/109). Despite the relatively small 
sample size, ASD was implicated in 36% of the pleiotropic loci. Most of the ASD 
associations co-occurred with SCZ and BIP. The other disorders, ADHD, TS, OCD, and 
AN featured associations in 16%, 14%, 11%, and 7% of the pleiotropic loci, 
respectively. Of the single-disorder-specific loci, 81% and 16% were associated with 
SCZ and MD, respectively.  
  
Table 2 summarizes 23 pleiotropic loci associated with at least four of the disorders. 
Among these loci, heterogeneity of effect sizes was minimal (p-value of Q > 0.1). Eleven 
of the 23 regions map to the intron of a protein-coding gene, and seven additional lead 
SNPs had at least one protein-coding gene within 100 kb. We used an array of 
functional genomics resources, including brain eQTL and Hi-C data to prioritize potential 
candidate genes to the identified regions (Online Methods; Fig. 2b). The Manhattan plot 
in Fig. 2c highlights the prioritized candidate genes.   
 
 
Table 2: SNP ID, location, prioritized candidate  gene, disorder-specific m-values and Odds ratios for 23 
most pleiotropic loci. The number of disorders with high confidence association (mDisorder_0.9) is shown 
in the last column. 
https://drive.google.com/open?id=18qFWLO7HdXf80zNqLBLJ4auXTrA101R8 
 
Of the 109 risk loci with shared effects, the 18q21.2 region surrounding SNP rs8084351 
at the netrin 1 receptor gene DCC featured the most pleiotropic association (Pmeta = 
4.26 x 10-12; Fig. 3a). This region showed association with all eight psychiatric 
disorders, and has been previously associated with both MD and neuroticism (Wray et 
al. 2018; Turley et al. 2018 PMID 29292387). The product of DCC plays a key role in 
guiding axonal growth during neurodevelopment and serves as a master regulator of 
midline crossing and white matter projections (Bendriem, 2017). Gene expression data 
indicate that DCC expression peaks during early prenatal development 
(Supplementary Fig. 4a).   
  
The second most pleiotropic locus in our analysis was identified in an intron of RBFOX1 
(RNA Binding Fox-1 Homolog 1) on 16p13.3 (lead SNP rs7193263; Pmeta = 5.59 x 10
-
11). The lead SNP showed association with all of the disorders except AN (Fig. 3b). 
RBFOX1 (also called A2BP1) encodes a splicing regulator mainly expressed in neurons 
and known to target several genes important to neuronal development, including NMDA 
receptor 1 and voltage-gated calcium channels (Hamada N, 2015). Knock-down and 
silencing of RBFOX1 during mouse corticogenesis impairs neuronal migration and 
synapse formation (Hamada N, 2015, 2016), implying its pivotal role in early cortical 
maturation. In contrast to DCC, however, developmental gene-expression of RBFOX1 
showed gradually increasing gene expression throughout the prenatal period 
(Supplementary Fig. 4b). Animal models and association studies have implicated 
RBFOX1 in aggressive behaviors, a trait observed in several of the disorders in our 
analysis ('Fernandez-Castillo, 2017 #12870). 
  
Of the 109 pleiotropic loci, 76 were identified in the GWAS of individual disorders, while 
the remaining 33 are novel. The most pleiotropic among these novel loci wasa region 
downstream of NOX4 (NADPH Oxidase 4) that was associated with SCZ, BIP, MD, 
ASD, and AN (rs117956829; Pmeta = 1.82 x 10
-9; Fig. 3c). Brain Hi-C data (Won, 2016, 
Wang et al. Science) detected a direct interaction of the cross-disorder association 
region with NOX4 in both adult and fetal brains (interaction p=3.2x10-16 and 9.324x10-6, 
respectively). As a member of the family of NOX genes that encode subunits of NADPH 
oxidase, NOX4 is a major source of superoxide production in human brain and a 
promoter of neural stem cell growth 'Topchiy, 2013 #12882} 'Kuroda, 2014 #12881}. 
  
Figure 3d illustrates another novel psychiatric risk locus associated with SCZ, BIP, 
ASD, and OCD (Pmeta = 3.58 x 10
-8). The lead SNP rs10265001 resides between 
MRPS33 (Mitochondrial Ribosomal Protein S33) and BRAF (B-Raf Proto-Oncogene, 
Serine/Threonine Kinase) on 7q34. The brain Hi-C data indicated interaction of the 
associated region with the promoters of two nearby genes: BRAF, which contributes to 
the MAP kinase signal transduction pathway and plays a role in postsynaptic responses 
of hippocampal neurons (Grantyn, 1973), and KDM7A (encoding Lysine Demethylase 
7A), which plays a central role in the nervous system and midbrain development 
(Horton, 2010; Qi, 2010; Tsukada, 2010).      
 
Our prior cross-disorder meta-analysis of five psychiatric disorders (Cross-Disorder Group 
of the Psychiatric Genomics Consortium, 2013) found no evidence of SNPs with 
antagonistic effects on two or more disorders. Here, we examined whether any variants 
with meta-analysis p ≤ 1x10-6 had opposite directional effects between disorders 
(Online Methods). After adjusting for having examined 206 loci across eight disorders (q 
< 0.001), we identified 11 loci with evidence of opposite directional effects on two or 
more disorders (Fig. 4; Supplementary Table. 6). The disorder configuration of 
opposite directional effects varied for the 11 loci, including three loci with opposite 
directional effects on SCZ and MD (rs301805, rs1933802, rs3806843), two loci between 
SCZ and ASD (rs9329221, rs2921036), and one locus (rs75595651) with opposite 
directional effects on the two mood disorders, BIP and MD. Notably, all of the six loci 
involving SCZ and BIP exhibited the same directional effect on the two disorders (Pbinom 
< 0.05), in line with their strong genome-wide genetic correlation.    
 
Figure 4. Eleven loci with opposite directional effects (could’t include in the 




Functional characterization of pleiotropic risk loci   
  
We conducted a series of bioinformatic analyses that examined whether loci with 
shared risk effects on multiple neuropsychiatric disorders had characteristic features 
that distinguished them from non-pleiotropic risk loci. First, we annotated the functional 
characteristics of 146 lead SNPs using various public data sources (Online Methods; 
Supplementary Table 7-9). Overall, they showed significant enrichment of genes 
expressed in the brain (beta=0.123, SE=0.0109, enrichment p = 1.22x10-29) and 
pituitary (beta=0.0916, SE=0.0136, p = 8.74 x 10-12), but not in the other Genotype-
Tissue Expression (GTEx) tissues. (Supplementary Table 10; Fig. 5a). A separate 
analysis of 109 pleiotropic risk loci also showed specific enrichment of genes expressed 
in multiple brain tissues (p = 1.55 x 10-5; Supplementary Table 11), while disorder-
specific loci showed nominally enriched brain gene expression in the cortex (p =2.14 x 






Figure 5. Results of functional genomics data analysis for pleiotropic vs. 
disorder-specific loci.  
 
Gene-set enrichment analyses using Gene Ontology data suggested involvement of 
pleiotropic risk loci in neurodevelopmental processes (Supplementary Table 13,14). 
The 109 pleiotropic risk loci were enriched for genes involved in neurogenesis (gene-set 
enrichment p = 9.67 x 10-6), regulation of nervous system development (p = 3.41 x 10-
5), and neuron differentiation (p = 3.30 x 10-5), while enrichment of these gene-sets was 
not seen for disorder-specific risk loci (adjusted enrichment p > 0.05). Pleiotropic risk 
loci also showed enrichment of genes involved in specific neurotransmitter-related 
pathways -- glutamate receptor signaling (p = 2.45 x 10-6) and voltage-gated calcium 
channel complex (p = 5.72 x 10-4) -- while non-pleiotropic risk loci, which were 
predominantly SCZ-associated, were over-represented among acetylcholine receptor 
genes (p = 7.25 x 10-8). Analysis of cortical gene expression data also suggested 
enrichment of pleiotropic risk genes in cortical glutamatergic neurons through layers 2-6 
(Supplementary Table 15), further supporting the shared role of glutamate receptor 
signaling in the pathogenesis of diverse neuropsychiatric disorders.  
  
In contrast to the differences in neuronal development and neuronal signaling pathways, 
pleiotropic and non-pleiotropic risk loci shared several characteristics related to genomic 
function. For instance, gene-set enrichment analyses indicated that both pleiotropic and 
non-pleiotropic risk loci were enriched for genes involved in the regulation of synaptic 
plasticity, neurotransmission, and synaptic cellular components.  
 
More than 41% of the genes associated with our genome-wide significant loci, both 
pleiotropic and non-pleiotropic, were intolerant of loss of function mutations (pLI score ≥ 
0.9); this is highly unlikely to occur by chance (Fisher’s exact p=4.90x10-8). This finding 
was consistent when examining pleiotropic (p=2.85x10-11) and non-pleiotropic risk loci 
(p=1.56x10-3)separately.        
 
Next, we compared spatio-temporal gene-expression patterns for the 109 pleiotropic 
risk loci and the 37 disorder-specific loci using post-mortem brain data. On average, 
disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 
both prenatal and postnatal development after multiple testing correction (t-test p > 
0.025 x10-2; Supplementary Fig. 5). During prenatal development, non-pleiotropic loci 
(mainly SCZ-associated) showed peak expression in the first trimester, after which 
expression rapidly decreased, while pleiotropic genes associated with only 2 disorders 
(“pleiotropy=2”; 60 loci) and those associated with more than 2 (“pleiotropy>2”, 49 loci) 
showed peak expression around the second trimester (Fig. 5b). After birth, all three 
groups showed gradually increasing gene expression until adulthood. Expression levels 
were associated with the degree of pleiotropy, with the pleiotropy>2 group showing 
higher gene expression than either the pleiotropy=2 group (t-test p < 2.10x10-4) or non-
pleiotropic risk loci (t-test p < 2.2x10-16).      
  
Enrichment analyses using the genes preferentially expressed in specific cortical 
regions suggested that pleiotropic loci were over-represented among genes expressed 
in the frontal cortex, while non-pleiotropic loci were enriched in the occipital cortex (FDR 
q<0.05; Fig. 5c). Cell-type-specific analysis indicated that genes implicated in 
pleiotropic loci were mainly expressed in neurons (FDR q<0.05) but not in glial cell 
types. Further, enrichment of pleiotropic loci in neuronal cells was also associated with 
the degree of pleiotropy, as highlighted in Fig. 5d.   
  
Previous studies of model organisms using gene knock-out experiments suggested that 
pleiotropic risk loci may undergo stronger selection than non-pleiotropic loci (Hill, 2012).  
However, we found no evidence that pleiotropic risk variants are under stronger 
evolutionary constraints (Supplementary Table 16). Various comparative genomics 
resources, including PhyloP (Pollard, 2010), PhastCons (Siepel, 2005), and GERP++ 
(Davydov, 2010), showed our top loci to have similar properties regardless of the extent 
of pleiotropy. Neither did we find differences between disorder-specific lead SNPs and 
pleiotropic SNPs with respect to their minor allele frequencies, average heterozygosity, 
or predicted allele ages (Kiezun, 2013). Pleiotropic and non-pleiotropic SNPs also did 
not differ in terms of the distance to nearest genes, distance to splicing sites, 
chromosome compositions, and predicted functional consequences of non-coding 
regulatory elements.   
 
Relationship between cross-disorder genetic risk and other brain-related traits 
and diseases   
To explore the genetic relationship of cross-disorder genetic risk with other traits, we 
treated this 8-disorder GWAS meta-analysis as a single “cross-disorder phenotype.” We 
applied LDSC to estimate SNP heritability (h2SNP) and genetic correlations with other 
phenotypes, using block jackknife-based standard errors to estimate statistical 
significance. The estimated h2SNP  of the cross-disorder phenotype was 0.146 (SE 
0.0058; observed scale). Using data for 28 brain-related traits selected from LDHub 
(Zheng et al., 2017), we found significant genetic correlations of the cross-disorder 
phenotype with seven traits (at a Bonferroni-corrected p-value threshold 0.002): 
never/ever smoking status, years of education, neuroticism, subjective well-being, and 
three sleep-related phenotypes (chronotype, insomnia, and excessive daytime 
sleepiness) (Supplementary Table 17).  
  
GWAS catalog data for the 109 pleiotropic risk loci showed enrichment of implicated 
genes in a range of brain-related traits (Supplementary Table 18). As expected, the 
associated traits included previous studies of neuropsychiatric disorders including SCZ, 
BIP, and ASD. In addition, they were enriched among genes previously associated with 
neuroticism (corrected enrichment p= 5.28x10-6; GRIK3, CTNND1, DRD2, RGS6, 
RBFOX1, ZNF804A, L3MBTL2, CHADL, RANGAP1, RSRC1, GRM3) and cognitive 
ability (corrected p= 7.15x10-5; PTPRF, NEGR1, ELOVL3, SORCS3, DCC, CACNA1I), 
and night sleep phenotypes (corrected p= 1.86x10-2; PBX1, NPAS3, RGS6, GRIN2A, 
MYO18A, TIAF1, CNTN4, PPP2R2B, TENM2, CSMD1). We also found significant 
enrichment of pleiotropic risk genes in multiple measures of body mass index (BMI), 
supporting previous studies suggesting a shared etiologic basis between a range of 
neuropsychiatric disorders and obesity (Hartwig et al. 2016; Rajan and Menon 2017; 
Guenzel and Schober 2017). 
 
DISCUSSION   
In the largest cross-disorder GWAS meta-analysis of neuropsychiatric disorders to date, 
comprising more than 725,000 cases and controls across eight disorders, we identified 
146 LD-independent lead SNPs associated with at least one disorder, including 35 
novel loci. Of these, 109 loci were found to affect two or more disorders, although 
characterisation of this pleiotropy is partly dependent on per-disorder sample size. Our 
results provide four major insights into the shared genetic basis of psychiatric disorders.  
  
First, modeling of genetic correlations among the eight disorders using two different 
methods (EFA and hierarchical clustering) identified three groups of disorders based on 
shared genomics: one comprising disorders characterized by compulsive behaviors 
(AN, OCD and TS), a second comprising mood and psychotic disorders (MD, BIP and 
SCZ), and a third comprising two early-onset neurodevelopmental disorders (ASD and 
ADHD) and one disorder each from the first two factors (TS and MD). The loading of 
MD on two factors may reflect biological heterogeneity within MD, consistent with recent 
evidence showing that early-onset depression is associated with genetic risk for ADHD 
and with neurodevelopmental phenotypes 'Rice, 2018 #12873}. Overall, these results 
indicate a substantial pairwise genetic correlation between multiple disorders along with 
a higher-level genetic structure that underlies psychopathology. These findings are at 
odds with the classical, categorical classification of mental illness.   
  
Second, variant-level analyses support the existence of substantial pleiotropy, with 
nearly 75% of the 146 genome-wide significant SNPs influencing more than one of the 
eight examined disorders. We also identified a set of 23 loci with particularly extensive 
pleiotropic profiles, affecting four or more disorders. The most highly pleiotropic loc‚us in 
our analyses, with evidence of association with all eight disorders, maps within DCC, a 
gene fundamental to the early development of white matter connections in the brain 
(Bendriem and Ross, 2017). Prior studies showed that DCC is a master regulator of 
axon guidance (through its interactions with netrin-1 and draxin (Liu et al., 2018). Loss 
of function mutations in DCC cause severe neurodevelopmental syndromes involving 
loss of midline commissural tracts and diffuse disorganization of white matter tracts 
(Bendriem and Ross, 2017; Jamuar et al., 2017; Marsh et al., 2017). A highly pleiotropic 
effect of variation in DCC on diverse psychiatric disorders with childhood and 
adolescent onset would be consistent with its role in both early organization of neuronal 
circuits and the maturation of mesolimbic dopaminergic connections to the prefrontal 
cortex during adolescence (Hoops and Flores, 2017; Reynolds et al., 2018; Vosberg et 
al., 2018).   
  
We also identified a set of loci that have opposite effects on risk of psychiatric disorders.  
Notably, these included loci with opposing effects on pairs of disorders that are 
genetically correlated and have common clinical features. For example, a SNP within 
MRSA was associated with opposing effects on two neurodevelopmental disorders 
(ASD and SCZ), and a variant within KIAA1109 had opposite directional effects on 
major mood disorders (BIP and MD) (Table 3). These results underscore the complexity 
of genetic relationships among related disorders and suggest that overall genetic 
correlations may obscure antagonistic biological mechanisms that operate at the level of 
component loci and pathways as seen in immune-mediated diseases (Baurecht et al., 
2015; Lettre and Rioux, 2008; Schmitt et al., 2016). This heterogeneity of effects 
between genetically correlated disorders is also consistent with a recent analysis that 
revealed loci contributing to biological differences between BIP and SCZ and found 
polygenic risk score associations with specific symptom dimensions (Bipolar et al., 
2018). 
  
Third, we found extensive evidence that neurodevelopmental effects underlie the cross-
disorder genetics of mental illness. In addition to DCC, a link between pleiotropy and 
genetic effects on neurodevelopment was also seen for other top loci in our analysis, 
including RBFOX1, BRAF, and KDM7A, all of which have been shown in prior research 
to influence aspects of nervous system development. Gene enrichment analyses 
showed that pleiotropic loci were distinguished from disorder-specific loci by their 
involvement in neurodevelopmental pathways including neurogenesis, regulation of 
nervous system development, and neuron differentiation. These results are consistent 
with those of a smaller recent analysis in the population-based Danish iPSYCH cohort 
(comprising 46,008 cases and 19,526 controls across six neuropsychiatric disorders) 
(Schork et al., 2017). In that analysis, consistent with the present findings, functional 
genomic characterization of cross-disorder loci implicated fetal neurodevelopmental 
processes, with greater prenatal than postnatal expression. However, the specific loci, 
cell types, and pathways implicated in the iPSYCH analysis differed from those 
identified in our study. Of note, however, SORCS3 emerged as a genome-wide 
significant cross-disorder locus in both studies.   
  
Fourth, our analyses of spatiotemporal gene expression profiles revealed that 
pleiotropic loci are enriched among genes expressed in neuronal cell types, particularly 
in frontal or prefrontal regions. They also demonstrated a distinctive feature of genes  
related to pleiotropic loci: compared with disorder-specific loci, they are on average 
expressed at higher levels both prenatally and postnatally (Figure 4). More specifically, 
single-disorder (mainly SCZ) loci were related to genes that were preferentially 
expressed in the first fetal trimester followed by a decline over the prenatal period and 
then relatively stable levels postnatally. In contrast, expression of genes related to  
pleiotropic loci peaked in the second trimester and remained overexpressed throughout 
the lifespan. When dividing the pleiotropic loci into bins of those associated with two 
disorders (mainly SCZ and BIP) vs. three or more disorders, we observed a consistent 
gradient of greater expression associated with broader pleiotropy.    
  
Taken together, our results suggest that pleiotropic loci appear to be distinguished by 
both their differential importance in neurodevelopmental processes and their heightened 
brain expression after the first trimester. Apart from this, however, pleiotropic loci were 
similar to non-pleiotropic loci across a range of other functional features, including 
intolerance to loss-of-function mutations, evidence of selection, minor allele frequencies, 
and genomic position relative to functional elements.     
  
Overall, our results identify a range of pleiotropic effects among loci associated with 
psychiatric disorders. Consistent with prior research (Brainstorm et al., 2018) (Cross-
Disorder Group of the Psychiatric Genomics et al., 2013), we found substantial pairwise 
genetic correlations across child- and adult-onset disorders and extended these findings 
by demonstrating clusters of genetically-related disorders. These results augment a 
substantial body of research demonstrating that genetic influences on psychopathology 
do not map cleanly onto the clinical nosology instantiated in the DSM or ICD (Smoller et 
al., 2018). Using a range of bioinformatic and functional genomic analyses, we find that 
loci with pleiotropic effects are distinguished by their involvement in early 
neurodevelopment and increased expression beginning in the second trimester of fetal 
development and persisting throughout adulthood. Taken together, the analyses 
presented here suggest that genetic influences on psychiatric disorders comprise at 
least two general classes of loci. The first comprises a set of genes that confer relatively 
broad liability to psychiatric disorders by acting on early neurodevelopment and the 
establishment of brain circuitry. These pleiotropic genes begin to come online by the 
second trimester of fetal development and exhibit differentially high expression 
thereafter. Such loci may underlie a latent general psychopathology factor (the “p” 
factor) (Caspi et al., 2014) that has been identified in developmental studies of mental 
disorders, comprising transdiagnostic symptom clusters (internalizing, externalizing, and 
psychotic) (Caspi et al., 2014). The expression and differentiation of this generalized 
genetic risk into discrete psychiatric syndromes (e.g., ASD, BIP, AN) may then involve 
direct and/or interactive effects of additional sets of loci and environmental factors, 
possibly mediated by epigenetic effects, that shape phenotypic expression via effects 
on brain structure/function and behavior. Further research will be needed to clarify the 
nature of such effects.   
  
Our results should be interpreted in light of several limitations. First, while our dataset is 
the largest genome-wide cross-disorder analysis to date, data available for individual 
disorders varied substantially—from a minimum of 9725 cases and controls for OCD to 
461,134 cases and controls for MD. This imbalance of sample size may have limited our 
power to detect pleiotropic effects on underrepresented disorders. Second, it is possible 
that comorbidity among disorders contributed to apparent pleiotropy; however we found 
that less than 2% of cases overlapped between disorder datasets (excluding 23andMe 
data) and we adjusted for overlap in meta-analysis. Second, the method we applied to 
detect cross-phenotype association, which combines an all-subsets fixed-effects GWAS 
meta-analysis with a Bayesian method for evaluating the best-fit configuration of 
genotype-phenotype associations, is one of several approaches (Solovieff et al., 2013). 
However, we have previously shown that this method outperforms a range of 
alternatives for detecting pleiotropy. (Zhu et al., 2018) Third, our designation of loci as 
pleiotropic vs. non-pleiotropic loci refers only to their observed effects on the eight target 
brain disorders. Thus, some of the “non-pleiotropic” loci may have additional effects on 
psychiatric phenotypes that were not included in our meta-analysis and/or on non-
psychiatric phenotypes. Fourth, our functional genomic analyses were constrained by 
the limitations of existing resources (e.g. spatiotemporal gene expression data 
resources). Our work underscores the need for more comprehensive functional data 
including single cell transcriptomic and epigenomic  profiles across development and 
brain tissues. Fifth, we included only individuals of European ancestry to avoid potential 
confounding due to ancestral heterogeneity across distinct disorder studies. Similar 
efforts are needed to examine these questions in other populations. 
  
In sum, in a large-scale cross-disorder genome-wide meta-analysis, we identified three 
genetic factors underlying the genetic basis of eight psychiatric disorders. We also 
identified 109 genomic loci with pleiotropic effects, of which 33 have not previously been 
associated with any of the individual disorders. In addition, we identified 11 loci with 
opposing directional effects on two or more psychiatric disorders. These results 
highlight disparities between our clinically-defined classification of psychiatric disorders 
and underlying biology. Finally, we found that genes associated with multiple psychiatric 
disorders are disproportionately associated with biological pathways related to 
neurodevelopment and exhibit distinctive gene expression patterns, with enhanced 
expression beginning in the second prenatal trimester and persistently elevated 
expression relative to less pleiotropic genes. Therapeutic modulation of pleiotropic gene 
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Figure Legends  
 
Figure 1. Genetic relationship between eight neuropsychiatric disorders. (A) SNP-
based genetic correlations (rg) were estimated between eight neuropsychiatric disorders 
using LDSC. The size of the circles scales with the significance of the p-values. The 
darker the color, the larger the magnitude of rg. Star sign (*) indicates statistical 
significance after Bonferroni correction. ADHD: attention-deficit/hyperactivity disorder; 
AN: anorexia nervosa; ASD: autism spectrum disorder; BIP: bipolar disorder; OCD: 
obsessive compulsive disorder; SCZ: schizophrenia. (B) SNP-based genetic 
correlations between eight disorders were depicted using an undirected graph to reveal 
complex genetic relationships than pairwise. Only significant genetic correlations in (A) 
were displayed. Each node represents a particular disorder, with edges indicating the 
strength of the pairwise correlations. The width of the edges increases, while the length 
decreases, with the absolute values of rg. (C) Based on results of an exploratory factor 
analysis of the genetic correlation matrix, a confirmatory factor model with three 
correlated genetic factors was specified using Genomic SEM and estimated with the 
weighted least squares algorithm. Two-headed arrows connecting the three factors to 
one another represent their correlations. Two-headed arrows connecting the genetic 
components of the individual psychiatric disorders to themselves represent residual 
genetic variances, and correspond to the proportion of heritable variation in liability to 
each individual psychiatric disorder that is unexplained by the three factors. 
Standardized parameters are depicted with their standard errors in parentheses. Paths 




Figure 2. Results of cross-disorder meta-analysis and candidate gene mapping. 
(A) Quantile-quantile (QQ) plot displaying the observed meta-analysis statistics vs. the 
expected ones under the null model of no associations in the -log10(p-value) scale. 
Although a marked departure is notable between the two statistics, the estimated 
lambda1000 and the estimated LD Score regression intercept indicate that the observed 
inflation is mainly due to polygenic signals rather than major confounding factors 
including population stratification. (B) Gene prioritization strategies for associated locus. 
Candidate genes were mapped on each locus if index SNP and credible SNPs reside 
within a protein-coding gene, are eQTL markers of the gene in the brain tissue, or 
interact with promoter regions of the gene based on brain Hi-C data. (C) Manhattan plot 
displaying the cross-disorder meta-analysis results highlighted with candidate genes 
mapped to top pleiotropic regions. 
 
Figure 3. Prediction of disorder-specific associations for illustrative pleiotropic 
loci: (A) rs8084351 on 18q21.2; (B) rs7193263 on 16p13.3; (C) rs117956829 on 
11q14.3; and (D) rs10265001 on 7q34. Results are presented for the two most 
pleiotropic loci (A, B) and two highly pleiotropic novel loci (C,D) For each locus, 
disorder-specific effects of the index SNP were presented using ForestPMPlot. The first 
panel is the forest plot, displaying disorder-specific association p-value, log odds ratio 
(OR), and standard errors of the SNP. The meta-analysis p-value and the 
corresponding summary statistic are displayed on the top and the bottom of the forest 
plot, respectively. The second panel is the PM-plot, in which the X-axis represents the 
m-value, the posterior probability that the effect exists in each disorder, and the Y-axis 
represents the disorder-specific association p-value as -log10(p-value). Disorders are 
depicted as a dot, of which the size represents the sample size of an individual GWAS. 
Disorders with an estimated m-value > 0.9 are colored in red, while those with an m-
value < 0.9 are marked in green.  
 
Figure 4. Eleven loci with opposite directional effects. The radius of each wedge 
corresponds to the absolute values of the Z-scores (log(Odds ratio)/S.E) obtained from 
association tests of the SNP for eight disorders. The color indicates whether the 




Figure 5. Results of functional genomics data analysis for pleiotropic vs. 
disorder-specific loci. (A) GTEX tissue-specific enrichment results for 109 pleiotropic 
risk loci. (B) Average gene-expression in brain cortical regions is depicted based on the 
pleiotropy level of the associated genes. The 147 genome-wide significant loci from the 
cross-disorder meta analysis were clustered into three groups based on predicted 
disorder-specific associations: (1) no-pleiotropy, (2) pleiotropy=2, and (3) pleiotropy>2. 
The “no-pleiotropy” group included 37 loci that showed a single-disorder-specific 
association, while the “pleiotropy=2” and “pleiotropy>2” groups included 60 and 49 loci 
that are associated with two and more than two disorders, respectively. (C) Brain 
developmental expression trajectory displayed for the three groups of genes based on 
the BrainSpan data. (D) Cortical regional enrichments calculated for the three gene 
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